Corona Immunitas was a Switzerland-wide, population-based SARS-CoV-2 study, assessing the seroprevalence and other study outcomes over six phases, starting in 2020 and ending in 2023. This entry describes the central database of study phases 1 to 4. Study phases 5 and 6 have been described elsewhere. This entry consists of the documentation of the database, the guide how to get access to the data, the description of available variables, and wording of survey questions, where applicable.Supporters (ordered alphabetically): Cantons of Basel-Landschaft, Basel-Stadt and Vaud CSS Versicherung Economiesuisse Ernst Göhner Stiftung Frontiers Helsana Versicherung Swiss Federal Office of Public Health Swiss School of Public Health (SSPH+) Symphasis ...
more than forty people died from the disease. A substantial database evolved as a consequence of con...
Corona Immunitas Nestlé is a longitudinal study conducted among employees at two Swiss sites of the ...
AIMS OF THE STUDY: A new emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was f...
Corona Immunitas was a Switzerland-wide, population-base SARS-CoV-2 study, assessing the seroprevale...
Objectives: Seroprevalence studies to assess the spread of SARS-CoV-2 infection in the general popul...
OBJECTIVES; : Seroprevalence studies to assess the spread of SARS-CoV-2 infection in the general pop...
Seroprevalence studies to assess the spread of SARS-CoV-2 infection in the general population and su...
The Elisa study is a population-based cohort study in Lübeck and the surrounding area (northern Germ...
Objectives: To describe the rationale, organization, and procedures of the Corona Immunitas Digital ...
In order to curb the rapid dissemination of the B.1.351 variant of SARS-CoV-2 in the district of Sch...
Objectives: To describe the rationale, organization, and procedures of the Corona Immunitas Digital ...
This dataset contains information on seven prospective cross-sectional nationwide residual sera coll...
Additional file 1: Supplemental Figure 1. Demographic information including sex, age group and regio...
This dataset contains information on seven prospective cross-sectional nationwide residual sera coll...
Corona Immunitas Fribourg aims at estimating the number and proportion of people who have been infec...
more than forty people died from the disease. A substantial database evolved as a consequence of con...
Corona Immunitas Nestlé is a longitudinal study conducted among employees at two Swiss sites of the ...
AIMS OF THE STUDY: A new emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was f...
Corona Immunitas was a Switzerland-wide, population-base SARS-CoV-2 study, assessing the seroprevale...
Objectives: Seroprevalence studies to assess the spread of SARS-CoV-2 infection in the general popul...
OBJECTIVES; : Seroprevalence studies to assess the spread of SARS-CoV-2 infection in the general pop...
Seroprevalence studies to assess the spread of SARS-CoV-2 infection in the general population and su...
The Elisa study is a population-based cohort study in Lübeck and the surrounding area (northern Germ...
Objectives: To describe the rationale, organization, and procedures of the Corona Immunitas Digital ...
In order to curb the rapid dissemination of the B.1.351 variant of SARS-CoV-2 in the district of Sch...
Objectives: To describe the rationale, organization, and procedures of the Corona Immunitas Digital ...
This dataset contains information on seven prospective cross-sectional nationwide residual sera coll...
Additional file 1: Supplemental Figure 1. Demographic information including sex, age group and regio...
This dataset contains information on seven prospective cross-sectional nationwide residual sera coll...
Corona Immunitas Fribourg aims at estimating the number and proportion of people who have been infec...
more than forty people died from the disease. A substantial database evolved as a consequence of con...
Corona Immunitas Nestlé is a longitudinal study conducted among employees at two Swiss sites of the ...
AIMS OF THE STUDY: A new emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was f...